Connect Biopharma Holdings Limited Increase (Decrease) in Accounts Payable
Connect Biopharma Holdings Limited (CNTB) reported Increase (Decrease) in Accounts Payable of $52.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$2.29M, a 255.04% decline year-over-year.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.34M, a 393.05% increase year-over-year.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$30.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$300.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for fiscal 2025 was $1.62M.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for fiscal 2024 was -$1.87M.
- Connect Biopharma Holdings Limited increase (decrease) in accounts payable for fiscal 2023 was -$1.14M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $52.00K 10-Q · filed 2026-08-12 | $22.00K derived: sum of 3 quarters · filed 2026-08-12 | -$278.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-12 | $2.31M derived: sum of 2 quarters · filed 2026-05-12 | $2.01M derived: sum of 3 quarters · filed 2026-05-12 | $3.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$330.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.15M derived: sum of 3 quarters · filed 2026-08-12 | $1.62M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.18M derived: sum of 2 quarters · filed 2026-08-12 | $1.65M 10-Q · filed 2025-11-12 | $1.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.95M 10-Q · filed 2026-08-12 | $1.91M derived: sum of 3 quarters · filed 2026-08-12 | $1.76M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $475.00K 10-Q · filed 2026-05-12 | $434.00K derived: sum of 2 quarters · filed 2026-05-12 | $287.00K derived: sum of 3 quarters · filed 2026-05-12 | $448.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$188.00K derived: sum of 2 quarters · filed 2026-03-31 | -$27.00K derived: sum of 3 quarters · filed 2026-03-31 | -$1.87M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.00K derived: sum of 2 quarters · filed 2025-11-12 | -$1.83M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.68M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$1.84M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$1.14M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |